Literature DB >> 12096167

Body weight changes associated with psychopharmacology.

Yelena Vanina1, Anna Podolskaya, Karim Sedky, Hasan Shahab, Abufarah Siddiqui, Firoz Munshi, Steven Lippmann.   

Abstract

OBJECTIVE: The authors discuss changes in body weight associated with various psychopharmaceuticals.
METHODS: A large number of articles and books about drug-induced changes in body weight, selected on the basis of various literature searches and the authors' clinical experiences with psychopharmaceuticals, were reviewed.
RESULTS: Many psychotropic drugs with antipsychotic, mood stabilizing, and antidepressant properties are associated with weight gain. Others, such as fluoxetine, isocarboxazid, nefazadone, topiramate, and psychostimulants, may cause weight loss. The antipsychotic drugs chlorpromazine, clozapine, and olanzapine are often associated with weight gain. Among antidepressants, amitriptyline and mirtazapine are known to cause weight gain. However, reductions are sometimes observed, and each antidepressant has its own unique weight-effect profile. Mood stabilizers, especially valproate-related products, are also associated with weight gain.
CONCLUSIONS: Careful monitoring and consideration of alternative therapies are essential.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096167     DOI: 10.1176/appi.ps.53.7.842

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  35 in total

1.  Efficacy, safety and cost of new drugs acting on the central nervous system.

Authors:  Silvio Garattini; Vittorio Bertele'
Journal:  Eur J Clin Pharmacol       Date:  2003-03-22       Impact factor: 2.953

2.  How can research ethics committees protect patients better?

Authors:  Silvio Garattini; Vittorio Bertele; Luca Li Bassi
Journal:  BMJ       Date:  2003-05-31

Review 3.  Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.

Authors:  Valentina Medici; Stephen A McClave; Keith R Miller
Journal:  Curr Gastroenterol Rep       Date:  2016-01

4.  The relationship between obesity and psychiatric disorders across ethnic and racial minority groups in the United States.

Authors:  Myra Rosen-Reynoso; Margarita Alegría; Chih-nan Chen; Mara Laderman; Robert Roberts
Journal:  Eat Behav       Date:  2010-09-21

Review 5.  What does the epidemic of childhood obesity mean for children with special health care needs?

Authors:  Paula M Minihan; Sarah N Fitch; Aviva Must
Journal:  J Law Med Ethics       Date:  2007       Impact factor: 1.718

6.  Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder.

Authors:  Jennifer E Wildes; Marsha D Marcus; Andrea Fagiolini
Journal:  Psychiatry Res       Date:  2008-09-07       Impact factor: 3.222

7.  Investigation of antidepressant medication usage after bariatric surgery.

Authors:  Julie L Cunningham; Cory C Merrell; Michael Sarr; Kristin J Somers; Donald McAlpine; Michael Reese; Susanna R Stevens; Matthew M Clark
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

8.  A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.

Authors:  Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow
Journal:  Pharmacol Biochem Behav       Date:  2015-01-29       Impact factor: 3.533

Review 9.  Psychotropic drugs in the treatment of obesity: what promise?

Authors:  Jose C Appolinario; João R Bueno; Walmir Coutinho
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.

Authors:  Chadi A Calarge; Vicki L Ellingrod; Bridget Zimmerman; Laura Acion; William I Sivitz; Janet A Schlechte
Journal:  Psychiatr Genet       Date:  2009-12       Impact factor: 2.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.